Other barks & bites for Friday, august 5: Win for AbbVie at Seventh Circuit; eleventh circuit affirms ruling for… IPWatchdog.com15:17Death Valley Pharma Energy/Utilities
Latest News

Yesterday
AbbVie surveys emotional impact of chronic leukemia condition, finds 'roller coaster' of emotions ENDPOINTS14:10 8-Aug-22
AbbVie continues with ‘extreme’ sporting Rinvoq TV ad theme as it runs ulcerative colitis… FiercePharma09:53 8-Aug-22
AbbVie invests big to retain leader position in TV ad spending and Botox makes a surprise… FiercePharma09:32 8-Aug-22
AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn PMLiVE07:46 8-Aug-22
AbbVie employees help to transform educational facilities at local national school Dublin People07:19 8-Aug-22
AbbVie, Sosei Heptares in $80 million G-protein-coupled receptor pact Chemical & Engineering News02:06 8-Aug-22
In the last 7 days
3 Unstoppable Dividend Stocks to Buy in August The Motley Fool06:16 6-Aug-22
Other Barks & Bites for Friday, August 5: Win for AbbVie at Seventh Circuit; Eleventh Circuit Affirms Ruling for… IPWatchdog.com15:17 5-Aug-22
Eli Lilly hit by migraine drug launch slowdown and a Reyvow no-show, but rivals Biohaven,… FiercePharma12:05 5-Aug-22
Fierce Pharma Asia—Sanofi's Innovent tie-up; Astellas' new medical chief; AbbVie's Sosei… FiercePharma10:54 5-Aug-22
3 Reasons Why AbbVie Stock Could Be Approaching a Make or Break Moment The Motley Fool10:05 5-Aug-22
3 Pharma Stocks' Post-Earnings Price Moves Entrepreneur Magazine09:12 4-Aug-22
Patent thickets not a problem, says US court in AbbVie case IAM08:47 4-Aug-22
Johnson & Johnson And AbbVie: 2 Great Dividend Aristocrats For What's Coming Next Seeking Alpha08:00 4-Aug-22
AbbVie’s Allergan reaches proposed $2.37bn agreement to settle US opioid lawsuits PMLiVE07:57 4-Aug-22
Global TNF Alpha Inhibitors Market Report 2022-2026 & 2031 Featuring Major Players - AbbVie, Amgen, J&J, UCB, Novartis, … GlobeNewswire (Press Release)07:05 4-Aug-22
Global Human Recombinant DNA Market Analysis Report 2022-2027 Featuring Abbvie, Alexion Pharmaceuticals, Amgen, Eli… GlobeNewswire (Press Release)06:45 4-Aug-22
Mayor and City Council of Baltimore v. AbbVie Inc. (7th Cir. 2022) JD Supra17:15 3-Aug-22
The Seventh Circuit Affirms Dismissal of the HUMIRA Antitrust Litigation JD Supra15:44 3-Aug-22
Sosei Bolsters GPCR Focus With AbbVie Neurology Deal Scrip Pharma Intelligence12:27 3-Aug-22
U.S. Prescription Drug Market Lacks Certain Competitive Features: Case Of Biosimilars Forbes10:37 3-Aug-22
Pharmalittle: AbbVie wins court opinion on Humira patent thickets; Alnylam heart disease drug… STAT09:34 3-Aug-22
What’s Happening With AbbVie Stock? Forbes09:08 3-Aug-22
FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition AbbVie (Press Release)08:53 3-Aug-22
Negotiations? AbbVie CEO says current drug pricing proposal brings 'price controls' instead FiercePharma08:46 3-Aug-22
Seventh Circuit Throws Out Antitrust Suit Against AbbVie in Welcome Victory for Patent Rights IPWatchdog.com08:11 3-Aug-22
Medicare drug pricing legislation likely to target AbbVie Crain's Chicago Business06:22 3-Aug-22
AbbVie likely to see negotiated drug pricing under bill • HCSC plans Medicare Advantage expansion • Monkeypox declared… Crain's Chicago Business06:22 3-Aug-22
Back for more: Sosei and Abbvie cut another $1B+ deal BioWorld17:14 2-Aug-22
U.S. appeals court panel decides AbbVie’s ‘patent thickets’ for Humira don’t thwart competition STAT15:56 2-Aug-22
'What’s wrong with having lots of patents?' Federal appeals judge sides with AbbVie in Humira case ENDPOINTS15:01 2-Aug-22
AbbVie’s Humira Patent Suit Survives Antitrust Appeal Competition Policy International14:40 2-Aug-22
AbbVie wins appeal in antitrust case over Humira 'patent thicket' Reuters14:20 2-Aug-22
AbbVie Submits Applications to EMA, FDA for Upadacitinib to Treat Crohn Disease Pharmacy Times13:38 2-Aug-22
AbbVie, bracing for biosim impact, scores another win against Humira antitrust allegations FiercePharma11:55 2-Aug-22
AbbVie and Sosei Lead Slate of Early August R&D Deals BioSpace11:33 2-Aug-22
Sosei Heptares and AbbVie to develop therapies for neurological ailments Pharmaceutical Technology10:03 2-Aug-22
AbbVie a Top Socially Responsible Dividend Stock With 4.0% Yield (ABBV) Nasdaq08:12 2-Aug-22
Why AbbVie Is A Top 25 Dividend Giant Forbes08:02 2-Aug-22
With some neuro targets in mind, AbbVie gets Sosei's drug discovery engine churning again ENDPOINTS07:13 2-Aug-22
AbbVie gives Sosei a StaRring role in neurological drug discovery plans, paying $40M and… FierceBiotech07:11 2-Aug-22
Employees of leading Sligo firm AbbVie spend a week painting at local gaelscoill The Sligo Champion07:07 2-Aug-22
AbbVie taps Sosei Heptares GPCR expertise with $1.2bn+ alliance pharmaphorum06:07 2-Aug-22
Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases Labiotech05:07 2-Aug-22
Sosei announces $1.2bn R&D collaboration with Abbvie European Biotechnology News04:01 2-Aug-22
Upadacitinib approval for ulcerative colitis given by MHRA Hospital Healthcare02:06 2-Aug-22
In the last month
BREAKING: 7th Circ. Declines To Revive Humira 'Patent Thicket' Claims Law36020:12 1-Aug-22
Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines… GlobeNewswire (Press Release)19:10 1-Aug-22
Hunter Shkolnik, Napoli Shkolnik Partner, and Opioid PEC Negotiating Team Colleagues Set Stage… Business Wire (Press Release)14:16 1-Aug-22
AbbVie's Allergan inks $2.3B+ opioid settlement with several states ENDPOINTS13:47 1-Aug-22
July’s Recovery or Bear Market Rally: Analyst Upgrades or Downgrades include AbbVie, Bumble,… 24/7 Wall St.11:58 1-Aug-22
AbbVie hit for marketing breaches, but PMCPA slaps down Vifor, Britannia for repeated failings FiercePharma10:50 1-Aug-22
Lilly, AZ, AbbVie and J&J face big potential hit from Medicare pricing bill: analysts FiercePharma10:30 1-Aug-22
AbbVie reports 4.5% rise in Q2 2022 net revenues Pharmaceutical Technology09:47 1-Aug-22
Merck And AbbVie Q2: Pipeline And Dividends In Focus Seeking Alpha08:45 1-Aug-22
AbbVie Stock Declined 4.2% on Friday Despite Upbeat Q2 Performance TipRanks06:12 1-Aug-22
AbbVie in $2 billion US opioid settlement Emerging Risks02:27 1-Aug-22
If You Invested $25,000 in Abbott Laboratories in 2013, This Is How Much You Would Have Today Nasdaq08:13 31-Jul-22
3 Dividend Aristocrats to Buy in August The Motley Fool06:05 31-Jul-22
3 Stocks We Think Could Beat the Market in the Second Half of 2022 The Motley Fool06:19 30-Jul-22
AbbVie (ABBV) Q2 2022 Earnings Call Transcript Nasdaq19:58 29-Jul-22
Why AbbVie Stock Is Tanking Today The Motley Fool18:27 29-Jul-22
AbbVie’s Gonzalez Sounds Alarm On US Drug Price Negotiation Proposal Scrip Pharma Intelligence17:55 29-Jul-22
AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag Nasdaq17:05 29-Jul-22
NorthShore to settle vaccine mandate lawsuit • AbbVie sales drop • Senators question Walgreens on birth control Crain's Chicago Business15:39 29-Jul-22
AbbVie's mixed quarter doesn't warrant a 5% stock drop. Here's why CNBC15:26 29-Jul-22
AbbVie, Novo Nordisk TV ads generate most searches in first half of 2022, ad tracker finds ENDPOINTS14:13 29-Jul-22
AbbVie Sets Aside $2B For Opioid Deal Law36013:18 29-Jul-22
AbbVie To Pay Up To $2.37 Billion To Settle U.S. Opioid Claims IBTimes (US)13:15 29-Jul-22
AbbVie stays bullish on future performance as Skyrizi continues to impress — but 'price controls' would be a game… ENDPOINTS13:12 29-Jul-22
AbbVie Slides After Cutting Sales Outlook on Cancer Drug Decline BNN Bloomberg13:11 29-Jul-22
AbbVie Shares Fall 6% Following Revenue Miss Investing.com12:27 29-Jul-22
AbbVie's Allergan in Pact for Opioid Settlement, NC AG Says MarketWatch12:22 29-Jul-22
In last Q2 with Humira market lock, AbbVie leans on best-seller to offset Imbruvica losses FiercePharma12:19 29-Jul-22
AbbVie sets aside $2bn to settle US opioid claims Financial Mail12:02 29-Jul-22
AbbVie (ABBV) Q2 Earnings Beat Estimates Nasdaq10:28 29-Jul-22
AbbVie Ekes Out Narrow Second-Quarter Beat, Confirms 2022 Outlook Investors Business Daily08:57 29-Jul-22
AbbVie Stock Slips After Earnings, Charge for Potential Opioid Deal Barron's Online08:57 29-Jul-22
AbbVie reports an increase in second-quarter revenue, led by sales of Humira MarketWatch08:28 29-Jul-22
AbbVie Confirms FY22 Adj. EPS Outlook - Update RTT News08:20 29-Jul-22
AbbVie sets aside $2 billion to settle U.S. opioid claims Investing.com08:12 29-Jul-22
AbbVie: Q2 Earnings Snapshot Associated Press08:01 29-Jul-22
AbbVie Earnings Beat, Revenue Misses In Q2 Investing.com07:51 29-Jul-22
AbbVie Reports Second-Quarter 2022 Financial Results AbbVie (Press Release)07:51 29-Jul-22
RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic… AbbVie (Press Release)02:15 29-Jul-22
UK-based AbbVie sales rep raises concerns about 'strategic loitering' outside hospitals during the pandemic ENDPOINTS14:54 28-Jul-22
AbbVie's Allergan to pay out more than $2 billion to resolve opioid litigation: Bloomberg FiercePharma12:24 28-Jul-22
Should You Buy AbbVie Ahead Of Earnings? Entrepreneur Magazine10:20 28-Jul-22
Pharmalittle: AbbVie’s Allergan reaches $2 billion deal on opioid lawsuits; internal IQVIA… STAT09:29 28-Jul-22
Allergan poised to pay more than $2 billion in opioid settlement resulting from Cleveland case Crain's Cleveland Business08:48 28-Jul-22
Global Thyroid Eye Disease Treatments Market Report to 2027 - Featuring AbbVie, Akron and AMRI Global Among Others GlobeNewswire (Press Release)06:42 28-Jul-22
AbbVie Q2 Preview: Can Shares Retain Their Strength? Nasdaq18:35 27-Jul-22
AbbVie’s Allergan reaches $2 billion opioid lawsuit settlement – Bloomberg News FX Empire18:31 27-Jul-22
AbbVie's Allergan reaches $2 bln opioid lawsuit settlement - Bloomberg News Reuters18:23 27-Jul-22
Allergan Poised to Pay More Than $2 Billion in Opioid Settlement BNN Bloomberg17:01 27-Jul-22
AbbVie submits regulatory applications to FDA and EMA for Upadacitinib in Crohn's Disease Daily Herald, Illinois16:53 27-Jul-22
AbbVie seeks nod from FDA and EMA for Crohn’s disease drug Labiotech15:03 27-Jul-22
AbbVie is scolded by a trade group over sales rep ‘strategically loitering’ in a hospital STAT14:27 27-Jul-22
Earnings Previews: AbbVie, Chevron, Exxon Mobil, Procter & Gamble 24/7 Wall St.12:59 27-Jul-22
AbbVie Seeks U.S., Europe OK of Rinvoq for Crohn's Disease >ABBV MarketWatch09:23 27-Jul-22
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's Disease AbbVie (Press Release)08:54 27-Jul-22
EC grants approval for AbbVie’s Rinvoq to treat ulcerative colitis in adults Pharmaceutical Technology07:13 27-Jul-22
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off The Motley Fool06:08 27-Jul-22
Abbvie, Istar team up to advance Miniject for glaucoma patients BioWorld17:09 26-Jul-22
AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards? Nasdaq11:46 26-Jul-22
Breast Reconstruction Market: Growing self-awareness and concerns regarding physical… PR Newswire (Press Release)07:30 26-Jul-22
Zacks Investment Ideas feature highlights: Coca-Cola, Emerson Electric and AbbVie Nasdaq06:24 26-Jul-22
Global Autoinjectors Market Report to 2027 - Players Include Mylan, AbbVie, Eli Lilly and Company & Ypsomed Holding GlobeNewswire (Press Release)06:21 26-Jul-22
Monoclonal Antibodies Market Size to Grow by USD 63.41 Bn, AbbVie Inc., and AstraZeneca Plc… PR Newswire (Press Release)04:27 26-Jul-22
European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative… AbbVie (Press Release)02:16 26-Jul-22
AbbVie and Allergan Aesthetics to present new data from leading neurotoxin portfolio conference Daily Herald, Illinois16:00 25-Jul-22
3 Safe Dividend Stocks to Buy in the Second Half of 2022 Entrepreneur Magazine12:16 25-Jul-22
Global Pharmaceutical Contract Manufacturing Market Report to 2027 - Featuring AbbVie, Amgen… Business Wire (Press Release)09:53 25-Jul-22
AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference AbbVie (Press Release)08:15 25-Jul-22
The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie Nasdaq07:51 25-Jul-22

      
            
      
    view more headlines
   
      
      
      
8 Aug 14:10
   
AbbVie News

NewsNow aims to be the world's most accurate and comprehensive aggregator of AbbVie news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications. Every story from every site is brought to you automatically and continuously 24/7, within around 10 minutes of publication. N.B. Relevance is automatically assessed so some headlines not qualifying as AbbVie news might appear - please feel free to contact us regarding any persistent issues.
AbbVie

Latest News

AbbVie News

Biotech Top Stories

Business Top Stories
